Abbott Laboratories is expecting its adult nutrition business to provide a meaningful boost to Q4 results, driven by recent product launches of Ensure Max Protein and Glucerna Hunger Smart. Internal forecasts project mid-single-digit revenue growth for the segment, building on a 4.8% increase in global adult nutrition sales during Q3. Management highlighted strong uptake in North America, where shelf-stable Ensure Max Protein postings rose 12% year-over-year in the month of October alone, and early customer feedback shows increased trial rates among consumers aged 50 and older.

In Q3, Abbott reported normalized EPS of $1.30, in line with Street expectations, while revenue climbed 6.9% year-over-year to $10.8 billion—falling short of consensus by $20 million. Core diagnostics and medical devices both posted healthy top-line gains of 8.2% and 5.5% respectively, offsetting a 2.1% dip in established pharmaceuticals. Operating margins expanded by 70 basis points, reflecting disciplined cost management and favorable mix shifts toward higher-margin diagnostic assays.

Abbott’s international regions outperformed domestic markets in Q3, delivering combined revenue growth of 9.4%. The Asia-Pacific division led with a 12.7% increase, propelled by new hospital wins for its Alinity family of diagnostic systems in South Korea and rising demand for point-of-care cardiovascular products in India. Latin America sales advanced 7.1%, supported by increased penetration of Ensure products in Brazil and Chile, setting a positive trajectory for multinational revenue streams in Q4.